Bayesian phase I/II adaptively randomized oncology trials with combined drugs
From MaRDI portal
(Redirected from Publication:641145)
Abstract: We propose a new integrated phase I/II trial design to identify the most efficacious dose combination that also satisfies certain safety requirements for drug-combination trials. We first take a Bayesian copula-type model for dose finding in phase I. After identifying a set of admissible doses, we immediately move the entire set forward to phase II. We propose a novel adaptive randomization scheme to favor assigning patients to more efficacious dose-combination arms. Our adaptive randomization scheme takes into account both the point estimate and variability of efficacy. By using a moving reference to compare the relative efficacy among treatment arms, our method achieves a high resolution to distinguish different arms. We also consider groupwise adaptive randomization when efficacy is late-onset. We conduct extensive simulation studies to examine the operating characteristics of the proposed design, and illustrate our method using a phase I/II melanoma clinical trial.
Recommendations
- A Bayesian adaptive design for addressing correlated late-onset outcomes in phase I/II randomized trials of drug combinations in oncology
- A Bayesian adaptive design in cancer phase I trials using dose combinations in the presence of a baseline covariate
- A Bayesian seamless phase I–II trial design with two stages for cancer clinical trials with drug combinations
- A hierarchical Bayesian design for phase I trials of novel combinations of cancer therapeutic agents
- Randomized phase III oncology trials: a survey and empirical Bayes inference
- Novel Bayesian Adaptive Designs and Their Applications in Cancer Clinical Trials
- A Bayesian adaptive phase I/II clinical trial design with late‐onset competing risk outcomes
- Bayesian phase II adaptive randomization by jointly modeling time-to-event efficacy and binary toxicity
Cites work
- scientific article; zbMATH DE number 1817583 (Why is no real title available?)
- scientific article; zbMATH DE number 1348603 (Why is no real title available?)
- scientific article; zbMATH DE number 3992730 (Why is no real title available?)
- A Parallel Phase I/II Clinical Trial Design for Combination Therapies
- A Strategy for Dose-Finding and Safety Monitoring Based on Efficacy and Adverse Outcomes in Phase I/II Clinical Trials
- A model for association in bivariate life tables and its application in epidemiological studies of familial tendency in chronic disease incidence
- Adaptive Rejection Metropolis Sampling within Gibbs Sampling
- Bayesian Dose-Finding in Phase I/II Clinical Trials Using Toxicity and Efficacy Odds Ratios
- Continual Reassessment Method: A Practical Design for Phase 1 Clinical Trials in Cancer
- Design and Analysis of Phase I Clinical Trials
- Designs for Single- or Multiple-Agent Phase I Trials
- Dose-Finding Based on Efficacy-Toxicity Trade-Offs
- Dose-finding designs for HIV studies
- Dose-finding with two agents in phase I oncology trials
- Statistical Inference Procedures for Bivariate Archimedean Copulas
- The Continual Reassessment Method for Multiple Toxicity Grades: A Bayesian Quasi‐Likelihood Approach
- Two‐Dimensional Dose Finding in Discrete Dose Space
Cited in
(22)- Combining Information from Cancer Registry and Medical Records Data to Improve Analyses of Adjuvant Cancer Therapies
- A Bayesian phase I/II trial design for immunotherapy
- Cancer phase I trial design using drug combinations when a fraction of dose limiting toxicities is attributable to one or more agents
- A three-stage Bayesian adaptive phase I/II design and simulation studies
- Bayesian dose regimen assessment in early phase oncology incorporating pharmacokinetics and pharmacodynamics
- Adaptive oncology Phase I trial design of drug combinations with drug-drug interaction modeling
- A Bayesian decision‐theoretic approach to incorporate preclinical information into phase I oncology trials
- ComPAS: a Bayesian drug combination platform trial design with adaptive shrinkage
- A Bayesian adaptive marker-stratified design for molecularly targeted agents with customized hierarchical modeling
- A phase I--II design based on periodic and continuous monitoring of disease status and the times to toxicity and death
- A phase I-II basket trial design to optimize dose-schedule regimes based on delayed outcomes
- A Bayesian seamless phase I–II trial design with two stages for cancer clinical trials with drug combinations
- A hybrid phase I-II/III clinical trial design allowing dose re-optimization in phase III
- Adaptive designs for drug combination informed by longitudinal model for the response
- A Parallel Phase I/II Clinical Trial Design for Combination Therapies
- Bayesian phase II adaptive randomization by jointly modeling time-to-event efficacy and binary toxicity
- A Bayesian adaptive design for addressing correlated late-onset outcomes in phase I/II randomized trials of drug combinations in oncology
- A flexible design for advanced phase I/II clinical trials with continuous efficacy endpoints
- A Bayesian adaptive phase I/II clinical trial design with late‐onset competing risk outcomes
- Bayesian hierarchical random-effects meta-analysis and design of phase I clinical trials
- Bootstrap aggregating continual reassessment method for dose finding in drug-combination trials
- Adaptive designs for selecting drug combinations based on efficacy-toxicity response
This page was built for publication: Bayesian phase I/II adaptively randomized oncology trials with combined drugs
Report a bug (only for logged in users!)Click here to report a bug for this page (MaRDI item Q641145)
